Axsome Therapeutics Inc . (NASDAQ:AXSM) stock soared to a 52-week high, reaching a price level of $105.18. The biopharmaceutical company, with a market capitalization of $5 billion, has demonstrated ...
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of ...
The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Invest with ...
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8 ...
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback